Insight Molecular Diagnostics
IMDX
47 hedge funds and large institutions have $21.1M invested in Insight Molecular Diagnostics in 2023 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 13 increasing their positions, 7 reducing their positions, and 11 closing their positions.
86% more repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 7
7% more capital invested
Capital invested by funds: $19.7M → $21.1M (+$1.4M)
0.44% more ownership
Funds ownership: 2.35% → 2.79% (+0.44%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
10% less funds holding
Funds holding: 52 → 47 (-5)
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BC
Broadwood Capital
New York
|
+$6.76M |
| 2 |
AIC
AWM Investment Company
New York
|
+$1.87M |
| 3 |
Morgan Stanley
New York
|
+$694K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$63.5K |
| 5 |
Geode Capital Management
Boston,
Massachusetts
|
+$59.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PVI
Pura Vida Investments
New York
|
-$136K |
| 2 |
PM
Penbrook Management
New York
|
-$73.6K |
| 3 |
BCM
Bridgeway Capital Management
Houston,
Texas
|
-$72.8K |
| 4 |
BlackRock
New York
|
-$53.7K |
| 5 |
Millennium Management
New York
|
-$34.5K |
IMDX Hedge Fund Activity: Q2 2023 in Review
47 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Insight Molecular Diagnostics (IMDX) for Q2 2023, worth a combined $21.1M — up 7.1% from $19.7M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of IMDX and 6 opened new positions — a net loss of 5 holders — while 7 trimmed existing stakes and 13 added.
The largest buyer was Broadwood Capital, adding an estimated $6.76M. The largest seller was Pura Vida Investments, cutting an estimated $136K.
- 47 institutional investors held Insight Molecular Diagnostics (IMDX) as of Q2 2023, down from 52 in Q1 2023.
- Funds reported $21.1M of Insight Molecular Diagnostics stock for Q2 2023, up 7.1% quarter-over-quarter.
- 6 funds opened new Insight Molecular Diagnostics positions in Q2 2023 and 11 closed out, a net change of -5 holders.
- The largest Insight Molecular Diagnostics buyer in Q2 2023 was Broadwood Capital, an estimated $6.76M added.
- The largest Insight Molecular Diagnostics seller in Q2 2023 was Pura Vida Investments, an estimated $136K sold.
Based on aggregated 13F filings for Q2 2023.